In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies named Nanotaxi® designed to unlock the promise of nucleic acids to treat acquired or inherited diseases, announces today successful completion of GMP fill and finish of Nanotaxi® vials and regulatory-enabling GLP safety evaluation (repeated dose toxicity, local tolerance and biodistribution) of their Nanotaxi® alone and Nanotaxi® formulated DNA immunotherapeutic candidate to treat hepatocellular carcinoma (“Hepavac”).
Download the full version of press release in English.